245 related articles for article (PubMed ID: 12602539)
1. Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation.
Torsello A; Locatelli V; Cella SG; Sanguini AM; Berti F
J Endocrinol Invest; 2003 Jan; 26(1):79-83. PubMed ID: 12602539
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
Friehe H; Ney P
Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232
[TBL] [Abstract][Full Text] [Related]
3. Acute and long-term dose-response study of quinapril on hormonal profile and tissue angiotensin-converting enzyme in Wistar rats.
Schaison FH; Fernando Ramirez-Gil J; Ciferri S; Bernard M; Baudin B; Mougenot N; Carayon A; Lechat P
J Cardiovasc Pharmacol; 1996 Jul; 28(1):11-8. PubMed ID: 8797130
[TBL] [Abstract][Full Text] [Related]
4. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
Edling O; Bao G; Feelisch M; Unger T; Gohlke P
J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
[TBL] [Abstract][Full Text] [Related]
5. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
Plosker GL; Sorkin EM
Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
[TBL] [Abstract][Full Text] [Related]
6. Pressure overload per se rather than cardiac angiotensin converting enzyme activity may be important in the development of rat cardiac hypertrophy.
Mukawa H; Toki Y; Shimauchi A; Matsui H; Morishima I; Okumura K; Ito T; Hayakawa T
J Hypertens; 1997 Sep; 15(9):1027-32. PubMed ID: 9321751
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats.
Fabris B; Yamada H; Cubela R; Jackson B; Mendelsohn FA; Johnston CI
Br J Pharmacol; 1990 Jul; 100(3):651-5. PubMed ID: 2167741
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue.
Fabris B; Chen BZ; Pupic V; Perich R; Johnston CI
J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S6-13. PubMed ID: 1691409
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors.
Johnston CI; Mendelsohn FA; Cubela RB; Jackson B; Kohzuki M; Fabris B
J Hypertens Suppl; 1988 Dec; 6(3):S17-22. PubMed ID: 2852234
[TBL] [Abstract][Full Text] [Related]
10. Heart failure development in rats with ascending aortic constriction and angiotensin-converting enzyme inhibition.
Turcani M; Rupp H
Br J Pharmacol; 2000 Aug; 130(7):1671-7. PubMed ID: 10928973
[TBL] [Abstract][Full Text] [Related]
11. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E
Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors.
Johnston CI; Fabris B; Yamada H; Mendelsohn FA; Cubela R; Sivell D; Jackson B
J Hypertens Suppl; 1989 Sep; 7(5):S11-6. PubMed ID: 2553899
[TBL] [Abstract][Full Text] [Related]
13. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril.
Palatini P; Racioppa A; Raule G; Zaninotto M; Penzo M; Pessina AC
Clin Pharmacol Ther; 1992 Oct; 52(4):378-83. PubMed ID: 1330398
[TBL] [Abstract][Full Text] [Related]
14. ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy.
Lear W; Ruzicka M; Leenen FH
Am J Physiol; 1997 Aug; 273(2 Pt 2):H641-6. PubMed ID: 9277479
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.
Sedman AJ; Posvar E
Angiology; 1989 Apr; 40(4 Pt 2):360-9. PubMed ID: 2539762
[TBL] [Abstract][Full Text] [Related]
16. Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster. Hemodynamic, morphological, and biochemical correlates.
Haleen SJ; Weishaar RE; Overhiser RW; Bousley RF; Keiser JA; Rapundalo SR; Taylor DG
Circ Res; 1991 May; 68(5):1302-12. PubMed ID: 1850330
[TBL] [Abstract][Full Text] [Related]
17. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure.
Squire IB; Macfadyen RJ; Lees KR; Hillis WS; Reid JL
Br J Clin Pharmacol; 1994 Aug; 38(2):117-23. PubMed ID: 7981011
[TBL] [Abstract][Full Text] [Related]
18. Modulation of incipient glomerular lesions in experimental diabetic nephropathy by hypotensive and subhypotensive dosages of an ACE inhibitor.
Fabris B; Candido R; Carraro M; Fior F; Artero M; Zennaro C; Cattin MR; Fiorotto A; Bortoletto M; Millevoi C; Bardelli M; Faccini L; Carretta R
Diabetes; 2001 Nov; 50(11):2619-24. PubMed ID: 11679443
[TBL] [Abstract][Full Text] [Related]
19. Chronic ACE inhibition by quinapril modulates central vasopressinergic system.
Muders F; Elsner D; Jandeleit K; Bahner U; Kromer EP; Kirst I; Riegger GA; Palkovits M
Cardiovasc Res; 1997 Jun; 34(3):575-81. PubMed ID: 9231041
[TBL] [Abstract][Full Text] [Related]
20. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats.
Nakajima T; Yamada T; Setoguchi M
J Cardiovasc Pharmacol; 1992 Jan; 19(1):102-7. PubMed ID: 1375675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
